ABSTRACT
In 1976, Caine et al. proposed a hypothesis for the use of α1-adrenoceptor antagonists in lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO), also referred to as symptomatic benign prostatic hyperplasia (BPH).1 By inhibiting the effect of noradrenaline-the neurotransmitter of the sympathetic nervous system-at α1-adrenoceptors in the bladder neck, prostatic urethra, and prostate capsule and stroma, α1-adrenoceptor antagonists reduce the dynamic component of BPH.1-3 Today, α1adrenoceptor antagonists are one of the most widely used medical therapies for this condition.3-5 They improve symptoms and urinary flow quickly (within a few weeks) and have a favorable clinical response in about 70% of patients. Total symptom score is in general improved by 30-40% and maximum urinary flow rate (Qmax) is increased by 16-25%.
